HUTCHMED announced the submission of a U.S. New Drug Application (NDA) for ORPATHYS® plus TAGRISSO® in MET-driven, EGFR-mutated lung cancer. The filing seeks U.S. regulatory consideration of the two-drug combination for this defined form of lung cancer.